Expert consensus document: Defining the major health modifiers causing atrial fibrillation: a roadmap to underpin

Larissa Fabritz1,2, Eduard Guasch3,4, Charalambos Antoniades5

  • 1Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.

Nature Reviews. Cardiology
|December 25, 2015
PubMed

Insights

Atrial fibrillation (AF) management lags behind understanding of its causes. This study proposes developing clinical markers reflecting AF mechanisms for personalized prevention and treatment strategies.

Area of Science:

  • Cardiology
  • Biomedical Research
  • Translational Medicine

Background:

  • Atrial fibrillation (AF) persists as a major cause of mortality and morbidity despite advances in treatment.
  • Current AF management relies on stroke risk, pattern, and symptoms, not underlying pathophysiology.
  • Significant knowledge exists on AF mechanisms including calcium dysregulation, fibrosis, and autonomic imbalance.

Purpose of the Study:

  • To bridge the gap between AF pathophysiology and clinical practice.
  • To propose a roadmap for developing clinical markers for AF causes.
  • To enable personalized AF prevention and treatment strategies.

Main Methods:

  • Literature review of AF mechanisms and clinical management.
  • Conceptual framework development for clinical marker identification.
  • Roadmap proposal for translating mechanistic insights into clinical tools.

Main Results:

  • Identified a disconnect between AF mechanistic understanding and current clinical management.
  • Proposed a strategy to develop clinical markers reflecting key AF drivers.
  • Outlined a path towards personalized AF care.

Conclusions:

  • Developing clinical markers based on AF pathophysiology is crucial.
  • Personalized strategies informed by these markers can improve AF patient care.
  • Translating mechanistic insights into actionable clinical tools is the future of AF management.

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
947
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
490
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
3.6K
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
613
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
580
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K